Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders by Hansen Wang
OPINION ARTICLE
published: 27 March 2014
doi: 10.3389/fnbeh.2014.00104
Lipid rafts: a signaling platform linking cholesterol
metabolism to synaptic deficits in autism spectrum
disorders
Hansen Wang*
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
*Correspondence: hansen.wang@utoronto.ca
Edited by:
Francesca Cirulli, Istituto Superiore di Sanità, Italy
Reviewed by:
Laura Ricceri, Istituto Superiore di Sanità, Italy
Keywords: cholesterol, lipid rafts, autism spectrum disorders, synaptic plasticity, fragile X syndrome, Rett syndrome, FMRP, statins
AUTISM AND CHOLESTEROL
METABOLISM
Autism spectrum disorders (ASDs) are a
group of developmental psychiatric dis-
orders characterized by impaired social
interaction and communication, and
by restricted, repetitive and stereotyped
behaviors and interests (Zoghbi and Bear,
2012; Ebert and Greenberg, 2013; Huguet
et al., 2013). Since the features of ASDs
usually manifest at the early childhood
when sensory experience is modifying
the development and balance of exci-
tatory and inhibitory synapses, it has
been hypothesized that ASDs may be due
to the disruption of experience depen-
dent synaptic development and function,
resulting in an imbalance between excita-
tion and inhibition in brain (Auerbach
et al., 2011; Zoghbi and Bear, 2012;
Delorme et al., 2013; Wang and Doering,
2013). Although genetic causes have been
identified in many individuals with ASDs,
the details about how those causal genes
converge on common pathways to alter
synaptic homeostasis in ASDs still need
to be investigated. Recently, Buchovecky
et al. described disturbances in choles-
terol homeostasis in animal model of the
ASD Rett syndrome (RTT), giving rise
to an exciting prospect that changes in
cholesterol metabolism might underlie the
development of ASDs (Buchovecky et al.,
2013).
Cholesterol, an essential cell membrane
component, influences the establishment
and maintenance of synaptic connection
and glial cell development in the nervous
system. Balanced cholesterol homeostasis
is an important aspect of nervous system
function (Mauch et al., 2001; Pfrieger,
2003; Linetti et al., 2010; Pfrieger and
Ungerer, 2011; Mathews et al., 2014)
(Figure 1A). Perturbed cholesterol home-
ostasis can affect neural development and
synaptogenesis and result in synaptic dys-
function, thus may lead to disorders of
nervous system (Simons and Ehehalt,
2002; Linetti et al., 2010; Pani et al., 2010;
Karasinska and Hayden, 2011). Evidence
from patients indicates that cholesterol
homeostasis could be altered in autis-
tic disorders. The Smith-Lemli-Opitz
Syndrome (SLOS), a genetic condition
of impaired cholesterol biosynthesis due
to mutations of the 7-dehydrocholesterol
reductase gene (DHCR7), has been found
to be associated with autism, supporting
genetic defects in cholesterol metabolism
can cause autism (Sikora et al., 2006;
Bukelis et al., 2007; Diaz-Stransky and
Tierney, 2012). Abnormal cholesterol
metabolism has also been observed in
patients with the ASD Asperger syndrome
and other nonsyndromic ASDs, suggest-
ing different abnormalities of cholesterol
metabolism may exist in ASDs (Tierney
et al., 2006; Dziobek et al., 2007). However,
little is known about the mechanisms
that mediate the abnormal cholesterol
metabolism in these ASD conditions.
RTT is caused largely by mutations
in the X-linked methyl CpG-binding
protein 2 gene (MECP2) (Baker et al.,
2013; Lyst et al., 2013; Xu and Pozzo-
Miller, 2013). In Mecp2 mutant mice,
Buchovecky et al. found that the expres-
sion of genes (Hmgcr, Sqle and Cyp46a1)
which encode key enzymes (3-hydroxy-3-
methylglutaryl-CoA reductase, squalene
epoxidase, CYP46A1) in the choles-
terol metabolic pathway and cholesterol
concentrations are altered in the brain
in a development dependent manner
(Buchovecky et al., 2013). Their study
indicates that loss of Mecp2 disrupts
cholesterol homeostasis, suggesting abnor-
mal cholesterol metabolism might be
involved in the pathogenesis of RTT (Nagy
and Ackerman, 2013). It thus links the
autism associated gene to cholesterol
metabolism, providing further insights
into the relationship between cholesterol
metabolism and ASDs.
CHOLESTEROL, LIPID RAFTS AND
SYNAPTIC PLASTICITY
Disturbances in cholesterol homeostasis in
ASDs raise the question of how changes in
cholesterol metabolism might be involved
in the development of autism. Cholesterol
is not uniformly distributed in biologi-
cal membranes, but concentrated in lipid
rafts, together with other lipids like sph-
ingolipids (Pfrieger, 2003; Fielding and
Fielding, 2004; Korade and Kenworthy,
2008; Pfrieger and Ungerer, 2011). Lipid
rafts, which are believed to act as plat-
forms for cellular signal transduction, have
been shown to play roles in synaptic plas-
ticity and contribute to neuropatholo-
gies, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington dis-
ease (HD) (Tsui-Pierchala et al., 2002;
Pfrieger, 2003; Korade and Kenworthy,
2008; Pani et al., 2010; Karasinska and
Hayden, 2011; Sebastiao et al., 2012).
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FIGURE 1 | Cholesterol metabolism, lipid rafts and autism spectrum
disorders. (A) Lipid rafts link cholesterol metabolism to synaptic signaling.
Cellular cholesterol is synthesized from acetyl-CoA in a multistep pathway,
with HMGCR and SQLE as the rate-limiting enzymes. In the adult brain,
cholesterol synthesis is attenuated in neurons that rely on astrocyte derived
cholesterol. Cholesterol and ApoE synthesized in astrocytes are secreted in
an ABCA1 dependent process, forming discoidal lipoprotein particles. ApoE is
(Continued)
Frontiers in Behavioral Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 104 | 2
Wang Cholesterol, lipid rafts and autism
FIGURE 1 | Continued
a ligand for LDLR family members, which mediate neuronal lipoprotein
uptake, thereby providing a supply of cholesterol to neurons. Excess
cholesterol is hydroxylated by CYP46A1 to 24-OHC, which diffuses into the
circulation. In astrocytes, 24-OHC binds to LXRs, which upregulate ApoE and
ABCA1 expression. Cholesterol synthesis is also linked to the mevalonate
pathway and produces Farnesyl-PP, which induces protein prenylation, a
posttranslational modification that is important for the function of signaling
proteins such as Ras and thus modulates protein synthesis. A mutated SQLE
attenuates phenotypes of animal model of the ASD Rett syndrome
(Buchovecky et al., 2013). Statins act at HMGCR and benefit animal models
of Rett syndrome and other ASDs including fragile X syndrome and
neurofibromatosis type 1 through inhibition of cholesterol synthesis and
mevalonate pathway (Li et al., 2005; Buchovecky et al., 2013; Osterweil et al.,
2013). Cholesterol is not evenly distributed in cell membranes. Lipid rafts are
membrane microdomains enriched in cholesterol. A great number of
presynaptic and postsynaptic proteins involved in neuronal communication
are localized to lipid rafts. Lipid rafts are critical for neurotransmitter release,
clustering of postsynaptic signaling molecules, protein trafficking and
communication between the cell membrane and cytoplasma. They modulate
the function of ionotropic receptors, G protein coupled receptors,
voltage-gated ion channels as well as neurotransmitter transporters.
Caveolae, a subset of lipid rafts that are flask-shaped membrane
invaginations and contain caveolins, is involved in lipid raft protein recycling,
sequestration and degradation (Allen et al., 2007; Pfrieger and Ungerer, 2011;
Sebastiao et al., 2012). (B) Representative autism linked signaling proteins
which are associated with lipid rafts. There is an increasing overlapping
between affected signaling molecules or pathways in ASDs and lipid raft
associated synaptic proteins as revealed by studies in autism genetics
(Huguet et al., 2013; Murdoch and State, 2013; Persico and Napolioni, 2013;
Schmunk and Gargus, 2013; Krumm et al., 2014; Ronemus et al., 2014) and
neurobiology (Wang et al., 2008b, 2010; Zoghbi and Bear, 2012; Delorme
et al., 2013; Ebert and Greenberg, 2013; Won et al., 2013) as well as research
in lipid rafts (Allen et al., 2007; Korade and Kenworthy, 2008; Pristera and
Okuse, 2011; Suzuki et al., 2011; Sebastiao et al., 2012; Liu et al., 2013).
These studies further support the functional link between lipid rafts and
synaptic deficits in ASDs. Abbreviations: 24-OHC, 24-hydroxycholesterol;
ABCA1, ATP-binding cassette transporter A1; ApoE, apolipoprotein E;
HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; SQLE, squalene
epoxidase; CYP46A1, cholesterol 24-hydroxylase; LDLR, LDL receptor; LXR,
liver X receptor; Farnesyl-PP, farnesyl pyrophosphate; GPCR, G protein
coupled receptors; VGIC, voltage-gated ion channels; NTT, neurotransmitter
transporters, BDNF, brain-derived neurotrophic factor; PSD, postsynaptic
density; ASD, autism spectrum disorder.
Cholesterol is a key component of lipid
rafts; its depletion disrupts lipid rafts and
leads to synaptic dysfunction or loss of
synapses (Mauch et al., 2001; Fielding and
Fielding, 2004; Korade and Kenworthy,
2008; Linetti et al., 2010; Pfrieger and
Ungerer, 2011; Pristera and Okuse, 2011;
Sebastiao et al., 2012). Since altered synap-
tic function is the common basis for
ASDs (Santoro et al., 2012; Zoghbi and
Bear, 2012; Delorme et al., 2013; Ebert
and Greenberg, 2013; Wang and Doering,
2013), it is likely that abnormal cholesterol
metabolism might be implicated in autism
through lipid raft disarrangements.
Lipid rafts are specialized membrane
structures that form an organized portion
of the membrane with concentrated sig-
naling molecules and link to the cytoskele-
ton (Simons and Toomre, 2000; Simons
and Ehehalt, 2002; Tsui-Pierchala et al.,
2002; Fielding and Fielding, 2004; Allen
et al., 2007; Korade and Kenworthy, 2008;
Lingwood and Simons, 2010; Simons
and Sampaio, 2011). The synapses, both
the presynaptic and postsynaptic sites,
are highly enriched in lipid rafts. Lipid
rafts not only contribute to neurotrans-
mitter exocytosis in presynaptic termi-
nals, but also postsynapticly modulate
neuronal signaling through clustering of
neurotransmitter receptors, ion channels
and components of downstream effec-
tors (Tsui-Pierchala et al., 2002; Korade
and Kenworthy, 2008; Linetti et al., 2010;
Pfrieger and Ungerer, 2011; Pristera and
Okuse, 2011; Sebastiao et al., 2012)
(Figure 1A). The postsynaptic density
(PSD), which is a massive multi-protein
complex whose functions include posi-
tioning signaling molecules for synaptic
plasticity, could be physically associated
with lipid rafts (Hering et al., 2003; Sheng
and Hoogenraad, 2007; Delint-Ramirez
et al., 2010; Sheng and Kim, 2011; Suzuki
et al., 2011; Liu et al., 2013). Numerous
PSD proteins such as NMDA receptors
(NR1, NR2A and NR2B), AMPA receptors
(GluR1 and GluR2), metabotropic glu-
tamate receptors (mGluRs), PSD-93/95,
CaMKII, and cadherin, are associated with
synaptic lipid rafts; notably, PSD-95 binds
to the postsynaptic neuroligins which
interact with the presynaptic neurexins,
providing a transsynaptic link between
PSD and presynaptic active zone (Hering
et al., 2003; Delint-Ramirez et al., 2010;
Sheng and Kim, 2011; Suzuki et al., 2011;
Liu et al., 2013). The association of PSD
with lipid rafts might be important in
signal integration and synaptic function.
Accumulating evidence has indicated that
precise localization of neurotransmitter
receptors, transporters, ion channels and
other synaptic proteins in lipid rafts can
be regulated by cholesterol and this reg-
ulation is critical for synaptic plasticity
(Tsui-Pierchala et al., 2002; Hering et al.,
2003; Allen et al., 2007; Linetti et al.,
2010; Pfrieger and Ungerer, 2011; Pristera
and Okuse, 2011; Sebastiao et al., 2012)
(Figure 1A). Importantly, many of the
lipid rafts associated signaling molecules
or pathways have been found to be impli-
cated in autism (Tsui-Pierchala et al.,
2002; Allen et al., 2007; Pristera and
Okuse, 2011; Sebastiao et al., 2012; Zoghbi
and Bear, 2012; Delorme et al., 2013;
Ebert and Greenberg, 2013; Huguet et al.,
2013; Schmunk and Gargus, 2013; Won
et al., 2013) (Summarized in Figure 1B).
Therefore, it is reasonable to postulate
that lipid rafts might serve as a plat-
form where cholesterol imbalance eventu-
ally causes neuronal and synaptic deficits
in ASDs (Wassif et al., 2001;Waage-Baudet
et al., 2005; Lee and Tierney, 2011).
CHOLESTEROL, LIPID RAFTS AND ASD
THERAPY
Interestingly, genetic or pharmacological
manipulation of cholesterol metabolism
has been found to alleviate ASD asso-
ciated animal behaviors. In the afore-
mentioned study, a mutagenesis screen in
Mecp2 mutant mice has identified that
a nonsense mutation in SQLE, which
is an obligate rate-limiting enzyme in
cholesterol biosynthesis, diminished some
of RTT related phenotypes (Buchovecky
et al., 2013). Statins reduce cholesterol
synthesis by interfering with cholesterol
synthesis through competitive inhibition
of HMGCR. Since cholesterol synthesis
is functionally tied to the mevalonate
pathway, statins also inhibit the synthe-
sis of isoprenoid intermediates farnesyl
pyrophosphate and ubiquinones, and thus
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affect protein modifications such as preny-
lation, which are important for the local-
ization and function of signaling proteins
such as Ras (van der Most et al., 2009;
Nagy and Ackerman, 2013). Due to their
impact on cholesterol synthesis and pro-
teinmodification, statins perturb the com-
position and properties of lipid rafts (van
der Most et al., 2009). These drugs might
exert effect on RTT animals as manipu-
lation of SQLE did. As expected, treat-
ment with statins did amelioratemetabolic
symptoms and improved animal motor
coordination and activity of the Mecp2
mutant mice (Buchovecky et al., 2013).
Noteworthily, the effect of statin treat-
ment has also been observed in animal
models of other ASDs, including fragile
X syndrome and neurofibromatosis type
1 (Li et al., 2005; Osterweil et al., 2013).
Group I mGluRs (mGluR1 and mGluR5)
are present in lipid rafts and play critical
roles in activity dependent synaptic plas-
ticity (Sebastiao et al., 2012; Wang and
Zhuo, 2012). In animal models of frag-
ile X syndrome, the activity of group I
mGluRs is abnormally enhanced, which
is causally linked to the pathogenesis of
this disease condition (Bear et al., 2004;
Wang et al., 2008a; Santoro et al., 2012;
Zoghbi and Bear, 2012). The scaffold-
ing protein caveolin in lipid rafts, alter-
ation in membrane cholesterol content
or perturbation of lipid rafts have been
shown to be able to regulate group I
mGluR trafficking and downstream sig-
naling pathways such as mitogen-activated
protein Kinases (MAPKs) (Francesconi
et al., 2009; Kumari et al., 2013). In
cultured neurons from fragile X mice,
group I mGluR dependent signaling was
attenuated by statins (Kumari et al.,
2013). Consistently, application of statins
reduced abnormally elevated protein syn-
thesis and mGluR-long term depression
(LTD) in hippocampal slices of fragile
X mice, attenuated audiogenic seizures
and corrected the hyperexcitability in the
visual cortex of these animals (Osterweil
et al., 2013). Apart from inhibition of sig-
naling molecules such as Ras signaling
for protein synthesis which has been sug-
gested by the investigators to underlie the
observed effects (Li et al., 2005; Osterweil
et al., 2013), statins may also benefit
ASD conditions through their action on
the cholesterol-lipid raft-mGluR pathway.
Taken together, these studies further sup-
port defective cholesterol homeostasis may
underlie the ASD phenotypes, suggesting
that cholesterol metabolism and lipid rafts
could be therapeutic targets for ASDs.
Considering the complexity and hetero-
geneity of autism, it will be necessary to
assess in future studies the effect of statin
treatment on the full spectrum of ASD
phenotypes.
CHALLENGES AND OPEN QUESTIONS
It is important to note, cholesterol may
regulate protein function not only through
altering lipid rafts but also by direct inter-
actions with the proteins. However, it is
very challenging to discriminate between
these possibilities for any specific type of
protein because it is unreasonable to test
the effect of cholesterol on the function
of a membrane protein in an environ-
ment without lipid rafts (Levitan et al.,
2010). Since cholesterol metabolism in
brain depends on the cooperation between
neurons and astrocytes, it will be neces-
sary to examine or manipulate cholesterol
metabolism and lipid rafts in individual
cell types (neurons or glial cells) of the
diseased brain (Korade and Kenworthy,
2008; Pfrieger and Ungerer, 2011). In view
of that lipid rafts could be potentially
modifiable by dietary cholesterol, ganglio-
sides, and fatty acids (Yaqoob and Shaikh,
2010), the relevance and significance of
those dietary supplements for ASD treat-
ment remains to be determined. Although
statins have shown to be promising for
ASD therapy, the timing, dosage and ideal
drugs will need to be identified in ani-
mal models or other preclinical trials to
facilitate the design of individualized ther-
apeutic strategy (Buchovecky et al., 2013;
Nagy and Ackerman, 2013; Osterweil et al.,
2013).
Despite the controversies in lipid raft
research, it is now clear that lipid rafts
which represent dynamic structural com-
ponents of cellular membranes do play
roles in neuronal signaling and that dys-
regulation of lipid rafts can lead to diseases
(Allen et al., 2007; Korade and Kenworthy,
2008; Pfrieger and Ungerer, 2011; Pristera
and Okuse, 2011; Sebastiao et al., 2012).
Due to complexity of ASD pathology and
etiology, the involvement of lipid rafts
in these disease conditions is not simple.
The disturbed cholesterol metabolism or
lipid raft aberrance may not exist in all
cases or every stage of the ASDs. Thus,
lipid rafts should not be seen as the sim-
plistic link between genetic defects and
synaptic dysfunction in autism. Additional
studies are definitely required to inves-
tigate cholesterol metabolism and lipid
raft abnormalities in ASDs and their
relevance to the pathophysiology and
treatment of these neurodevelopmental
disorders. These studies will need to com-
bine biochemical, biophysical, imaging,
behavioral, genetic and pharmacological
techniques to advance our understanding
and therapeutics of autism.
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